Mentored Clinical Research to Improve Outcomes for Pediatric Mature B Cell Lymphoma in Uganda

指导临床研究以改善乌干达儿童成熟 B 细胞淋巴瘤的治疗结果

• 批准号: 10621584
• 负责人: CARL E ALLEN
• 金额: $ 12.5万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-25 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10621584
• 关键词: AIDS related cancer; AIDS/HIV problem; Accreditation; Address; Africa South of the Sahara; African; B-Cell Lymphomas; B-Cell NonHodgkins Lymphoma; Biologic Characteristic; Botswana; Caring; Child; Childhood; Clinical; Clinical Research; Clinical Trials Network; Country; Development; Diagnosis; Disease; Educational Curriculum; Enrollment; Epidemic; Fellowship; Fellowship Program; Foundations; Goals; HIV; Health Sciences; International; Malawi; Malignant Childhood Neoplasm; Mature B-Lymphocyte; Medicine; Mentors; Mentorship; NCI Center for Cancer Research; Oncology; Outcome; Parents; Patient-Focused Outcomes; Patients; Pediatric Cancer Care Network; Pediatric Hematology; Pediatric Hospitals; Pediatric Oncologist; Physicians; Research; Research Training; Site; Standardization; Tanzania; Texas; Training; Training Programs; Treatment Protocols; Uganda; Universities; college; experience; improved; improved outcome; infection related cancer; interest; lecturer; pediatric human immunodeficiency virus; pediatrician; programs; response; risk stratification

Project Summary/Abstract This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA- 22-036. Outcomes for children with cancer in sub-Saharan Africa (SSA) are unacceptably poor, with fewer than 20% of those diagnosed surviving. By contrast, over 85% of children with cancer in the US survive. The HIV epidemic complicates the landscape of pediatric malignancies in SSA. In partnership with collaborators in SSA, Global HOPE aims to lay the foundation for an international collaborative clinical trial network: Pediatric HIV/AIDS & Infection-Related Malignancies Research Consortium for Sub-Saharan Africa (PARCA). The central problem faced in SSA is the significant burden of HIV-associated malignancies in children and the poor survival of these patients. Global HOPE, a program developed by Baylor College of Medicine (BCM) and Texas Children’s Hospital (TCH), addresses systemic challenges to improve patient outcomes by facilitating the development of a network of pediatric cancer care and research centers across SSA, starting with sites in Uganda, Malawi, Botswana, and Tanzania. Global HOPE focuses on capacity-building and has partnered with the internationally recognized Makerere University College of Health Sciences (MakCHS) in Uganda to create a first-of-its-kind collaborative pediatric hematology-oncology (PHO) training hub. In 2016, Makerere College of Health Sciences (MakCHS) and Global HOPE implemented the first accredited PHO physician postgraduate clinical fellowship training program in SSA. To date, 24 pediatricians from eight African countries have enrolled in this two-year PHO fellowship training Program. Fourteen graduates from the program are currently leading PHO care teams at 7 centers in 4 countries in SSA. In this application, we propose to take advantage of PARCA to support clinical research training of Dr. Anne Akullo, a recent Ugandan graduate of the MakCHS PHO fellowship program, with a mentorship team including Dr. Ruth Namazzi (Lecturer, MakCHS, and Director of the Pediatric Hematology- Oncology Fellowship Program at Makerere University, Kampala, Uganda) and clinical research experts from Houston and Uganda. The overall goal of the parent U54 is to establish a standardized multi-site strategy to deliver safe and effective disease-specific and risk-stratified care to children with mature B cell non-Hodgkin lymphoma (MB-NHL) in SSA. Dr. Akullo’s training will include personalized curriculum and mentored research experience focusing on clinical research goals of Project #3 of the PARCA U54 in Uganda: To investigate clinical and biological characteristics associated with clinical outcomes of children with MB-NHL treated on standardized PARCA treatment regimens.

项目摘要/摘要 本申请是为了回应被确认为非CA-CA的特殊利益通知(NOSI)而提交的 22-036。撒哈拉以南非洲(SSA)癌症儿童的结果令人无法接受地糟糕，只有不到 确诊的患者中有20%幸存下来。相比之下，美国超过85%的癌症儿童存活下来。艾滋病病毒 流行病使SSA儿童恶性肿瘤的情况变得更加复杂。与SSA的合作者合作， 全球希望旨在为国际协作临床试验网络奠定基础：儿科艾滋病毒/艾滋病 和撒哈拉以南非洲感染相关恶性肿瘤研究联盟(PARCA)。中心问题 SSA面临的是儿童艾滋病毒相关恶性肿瘤的沉重负担，以及这些疾病的低存活率 病人。全球希望，这是由贝勒医学院(BCM)和德克萨斯州儿童医院共同开发的项目 医院(TCH)，通过促进发展，解决改善患者预后的系统性挑战 整个南沙地区的儿科癌症护理和研究中心网络，从乌干达、马拉维、 博茨瓦纳和坦桑尼亚。全球希望专注于能力建设，并与国际上的 乌干达公认的Makerere大学健康科学学院(MakCHS)创建了首个此类学院 协作式儿科血液肿瘤(Pho)培训中心。2016年，马凯雷尔健康科学学院 (MakCHS)和Global Hope实施了第一个经认可的PHO医生研究生临床奖学金 SSA的培训计划。到目前为止，来自8个非洲国家的24名儿科医生已经报名参加了这个为期两年的课程 PHO奖学金培训计划。该项目的14名毕业生目前领导着pho护理团队。 在SSA的4个国家的7个中心。在这个应用中，我们建议利用PARCA来支持临床 Anne Akullo博士，最近从MakCHS pho奖学金方案毕业的乌干达人，参加了 包括Ruth Namazzi博士(MakCHS讲师兼儿科血液学主任- 乌干达坎帕拉Makerere大学的肿瘤学奖学金计划)和来自 休斯顿和乌干达。母公司U54的总体目标是建立标准化的多站点战略，以 为患有成熟B细胞非霍奇金的儿童提供安全有效的针对疾病和风险分层的护理 SSA淋巴瘤(MB-NHL)。阿库洛博士的培训将包括个性化课程和指导性研究 关注乌干达PARCA U54项目#3临床研究目标的经验：临床调查 与标准化治疗的MB-NHL儿童的临床结果相关的生物学特征 帕尔卡治疗方案。